ロード中...
Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare
PURPOSE: Beginning in July of 2018, the FDA issued a voluntary recall regarding the presence of a contaminant found in the manufacturing of valsartan. What would ensue has become a largely unprecedented sequence of alarming events since the FDA began reporting public recalls, withdrawals and safety...
保存先:
| 出版年: | Cardiovasc Drugs Ther |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7171054/ https://ncbi.nlm.nih.gov/pubmed/32318933 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-020-06976-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|